CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Samsung Bio to step into peptides in $1.8B buy for PolyPeptide

Positive
AI Analysis

Summary

Samsung Biologics announced plans to acquire Swiss CDMO PolyPeptide for $1.8 billion in cash to expand into peptide ingredient manufacturing.

Importance:7/10
Sentiment:
0.50
M&ACDMOpeptidesacquisitionSamsung BiologicsPolyPeptide

Read the original article

Published by Endpoints News on July 20, 2026 4:18 PM

Read Original